	UCB plots regulatory filings as Fintepla shows potential to treat a 3rd epilepsy disorder
	UCB at 42: Chairman Sharif Zahir redefines reforms, recovery and the road ahead
	UCB pursues approval of Fintepla in CDKL5 deficiency following Phase III study
	UCB Q1 Deep Dive: Deposit Growth and Margin Expansion Drive Solid Start to 2025
	UCB shares promising results for fenfluramine in ultra-rare form of epilepsy
	UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
	UCB eyes sustainable profitability within two years
	UCB reports success in phase 3 study of fenfluramine for CDD